Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Neoplasms 28Lung Neoplasms 24Neoplasm Metastasis 12Mesothelioma, Malignant 11Mesothelioma 10Colorectal Neoplasms 10Ovarian Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Melanoma 5Head and Neck Neoplasms 5Breast Neoplasms 5Adenocarcinoma of Lung 5Pancreatic Neoplasms 4Carcinoma 4Advanced Cancer 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Lymphoma, Non-Hodgkin 3Lymphoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Advanced Solid Tumors 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2

Interventions

ficlatuzumab 1Pemetrexed 1MRX-2843 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplastic Processes × Pemetrexed × Clear all
NCT00692159 2010-09-10

Study of TRC102 in Combination With Pemetrexed in Cancer Patients

Tracon Pharmaceuticals Inc.

Phase 1 Completed
28 enrolled
Other neoplasm

Neoplasms, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡